Free Trial
NASDAQ:SCPS

Scopus BioPharma (SCPS) Stock Price, News & Analysis

Scopus BioPharma logo
$0.0004
0.00 (0.00%)
(As of 10/31/2024 ET)

About Scopus BioPharma Stock (NASDAQ:SCPS)

Key Stats

Today's Range
$0.0004
$0.0004
50-Day Range
N/A
52-Week Range
$0.00
$0.06
Volume
66,664 shs
Average Volume
5,625 shs
Market Capitalization
$16,833.60
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

Scopus BioPharma Inc., a clinical-stage biopharmaceutical company, focuses on developing transformational therapeutics targeting serious diseases with unmet medical needs. It offers Duet Platform, which consists of signal transducer and activator of transcription 3 (STAT3), a master immune checkpoint inhibitor and toll-like receptor 9 (TLR9), as well as includes CpG-STAT3ASO (DUET-02), CpG-STAT3siRNA (DUET-01), and CpG-STAT3decoy (DUET-03); and that develops a suite of bifunctional oligonucleotides that activate antigen-presenting cells (APCs) in the tumor microenvironment that alleviates tumor immunosuppression to jump-start T cell-mediated immune responses. The company is also developing DUET-01, as a monotherapy targeting B-cell non-Hodgkin lymphoma; DUET-02 that provides systemic delivery for treatment of solid tumors comprising prostate or kidney cancers; and DUET-03, which targets the actual STAT3 transcription factor protein. Scopus BioPharma Inc. has licensing agreements with the City of Hope, National Institutes of Health Program, and The Hebrew University of Jerusalem. The company was formerly known as Project18 Inc. and changed its name to Scopus BioPharma Inc. in December 2017. Scopus BioPharma Inc. was incorporated in 2017 and is headquartered in New York, New York.

Receive SCPS Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Scopus BioPharma and its competitors with MarketBeat's FREE daily newsletter.

SCPS Stock News Headlines

Tim Sykes’ Urgent Trade Alert: “Make this move now”
WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT about Trump or Biden dropping out of the race…
Scopus Biopharma Inc (SCPS)
ArriVent BioPharma Inc AVBP
Scopus BioPharma Inc. (SCPS)
See More Headlines

SCPS Stock Analysis - Frequently Asked Questions

Scopus BioPharma's stock was trading at $0.0431 on January 1st, 2024. Since then, SCPS stock has decreased by 99.1% and is now trading at $0.0004.
View the best growth stocks for 2024 here
.

Shares of SCPS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

Based on aggregate information from My MarketBeat watchlists, some other companies that Scopus BioPharma investors own include Plug Power (PLUG), Canoo (GOEV), NIO (NIO), SNDL (SNDL), Tesla (TSLA), Moderna (MRNA) and VYNE Therapeutics (VYNE).

Company Calendar

Today
10/31/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:SCPS
Fax
N/A
Employees
9
Year Founded
N/A

Profitability

Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Book Value
($0.33) per share

Miscellaneous

Free Float
39,938,000
Market Cap
$16,833.60
Optionable
Not Optionable
Beta
-0.01
A Guide To High-Short-Interest Stocks Cover

MarketBeat's analysts have just released their top five short plays for November 2024. Learn which stocks have the most short interest and how to trade them. Click the link below to see which companies made the list.

Get This Free Report

This page (NASDAQ:SCPS) was last updated on 10/31/2024 by MarketBeat.com Staff
From Our Partners